C. Cutler

发表

Long-Term Utilization Patterns Of Topical Therapy And Clinical Outcomes Of Oral Chronic Graft-Versus-Host Disease.

N. Treister, M. A. Shazib, J. Muhlbauer, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.

R. Soiffer, Stephanie J. Lee, S. Sonis, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report.

L. Gerber, J. Bolaños-Meade, Stephanie J. Lee, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.

P. Richardson, D. Zahrieh, D. DeAngelo, 2003, Blood.

Survival following allogeneic transplant in patients with myelofibrosis.

N. Kröger, M. Arcasoy, S. Verstovsek, 2020, Blood advances.

Peripheral-blood stem cells versus bone marrow from unrelated donors.

P. Westervelt, S. Mineishi, D. Porter, 2012, The New England journal of medicine.

Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review

C. Cutler, J. Antin, 2001, Stem cells.

Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, J. Whangbo, 2019, Blood advances.

Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.

J. Ritz, R. Soiffer, Gregory Bascug, 2010, The Journal of clinical investigation.

Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients

R. Clark, R. Watanabe, D. Fisher, 2012, Science Translational Medicine.

Inhibition of Inositol kinase B controls acute and chronic graft-versus-host disease.

J. Ritz, D. Munn, J. Serody, 2019, Blood.

Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation

J. Ritz, K. Ballen, T. Karantanos, 2019, Bone Marrow Transplantation.

Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells

M. Sadelain, M. Geyer, J. Liesveld, 2018, Leukemia & lymphoma.

Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT

R. Kwong, E. Neufeld, P. Armand, 2013, Bone Marrow Transplantation.

Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.

M. Fleming, H. Steen, R. Kwong, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report.

J. Ritz, J. Pidala, H. Greinix, 2021, Transplantation and cellular therapy.

A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation

J. Ritz, D. Miklos, H. Nakasone, 2019, Haematologica.

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.

M. Norkin, H. Nakasone, M. Aljurf, 2018, Blood advances.

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

A. Logan, D. Miklos, M. Flowers, 2017, Blood.

Oral chronic GVHD outcomes and resource utilization: a subanalysis from the chronic GVHD consortium.

J. Pidala, M. Arora, N. Treister, 2016, Oral diseases.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

H. Greinix, Stephanie J. Lee, M. Flowers, 2015 .

Providing personalized prognostic information for adult leukemia survivors.

Alan M. Miller, B. Storer, B. George, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.

B. Kurland, J. Pidala, Stephanie J. Lee, 2012, Blood.

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.

B. Storer, J. Pidala, Stephanie J. Lee, 2011, Blood.

Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.

J. Klein, M. Horowitz, J. Wingard, 2011, Blood.

Oral chronic graft-versus-host disease scoring using the NIH consensus criteria.

K. Stevenson, R. Soiffer, N. Treister, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chronic graft-versus-host disease

C. Cutler, J. Antin, 2006, Current opinion in oncology.

Quality of life associated with acute and chronic graft-versus-host disease

R. Soiffer, C. Cutler, Haesook T. Kim, 2006, Bone Marrow Transplantation.

Reduced Intensity Transplants for Lymphoma : Reduced Intensity versus Full Transplant 9

B. Sandmaier, J. Dipersio, C. Bollard, 2013 .

GM-CSF Secreting Leukemia Cell Vaccination after Allogeneic Reduced Intensity Hematopoietic Stem Cell Transplantation for Advanced Myeloid Malignancies

G. Dranoff, R. Soiffer, Matthew W. Vanneman, 2008 .

GM-CSF Secreting Leukemia Cell Vaccinations after Allogeneic Reduced-Intensity Peripheral Blood Stem Cell Transplantation (SCT) for Advanced Myelodysplastic Syndrome (MDS) or Refractory Acute Myeloid Leukemia (AML).

G. Dranoff, R. Soiffer, C. Cutler, 2006 .

Peer support in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT): a qualitative study

L. Traeger, E. Feig, Lauren E. Harnedy, 2022, Bone Marrow Transplantation.

Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia.

C. Cutler, 2014, Hematology. American Society of Hematology. Education Program.

Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation

D. Neuberg, B. Ebert, K. Hsu, 2017, The New England journal of medicine.

Fit Older Adults with Advanced Myelodysplastic Syndromes: Who is Most Likely to Benefit from Transplant?

G. Abel, D. DeAngelo, R. Soiffer, 2020, Leukemia.

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.

M. Aljurf, R. Gale, K. Ballen, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Alan M. Miller, R. Vij, W. Wood, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #110

E. Leifer, F. Appelbaum, M. Horowitz, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services.

M. Horowitz, D. Weisdorf, C. Cutler, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome.

C. Cutler, 2010, Hematology. American Society of Hematology. Education Program.

Towards a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force.

B. Banas, G. Cuvelier, W. Kimberly, 2022, Transplantation and cellular therapy.

Donor and Recipient Plasma Follistatin Levels are Associated with Acute Graft-versus-Host Disease in Blood and Marrow Transplant Clinical Trials Network 0402

G. Vercellotti, M. MacMillan, Juan Wu, 2017, Bone Marrow Transplantation.

Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials.

R. Hills, B. Djulbegovic, D. Blaise, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions

P. Altevogt, G. Dranoff, J. Ritz, 2014, Clinical Cancer Research.

W. Wood, B. Storer, J. Pidala, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Matching at HLA-C improved the outcomes after double umbilical cord blood transplantation for recipients of 2–4/6 HLA-matched grafts

J. Wagner, K. Ballen, R. Soiffer, 2017 .

90Y-Ibritumomab tiuxetan followed by reduced-intensity conditioning and allogeneic stem-cell transplantation in patients with advanced follicular lymphoma

A. LaCasce, A. Freedman, K. Stevenson, 2010, Bone Marrow Transplantation.

Rituximab for prevention and treatment of graft-versus-host disease

C. Cutler, M. Kharfan-Dabaja, 2011, International journal of hematology.

Rituximab for steroid-refractory chronic graft-versus-host disease.

J. Ritz, D. Miklos, D. Bienfang, 2006, Blood.

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.

D. Neuberg, Catherine J. Wu, G. Dranoff, 2013, The Journal of clinical investigation.

Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation

J. Kutok, M. Mihm, G. Dranoff, 2009, Proceedings of the National Academy of Sciences.

Expression of CD30 in patients with acute graft-versus-host disease.

J. Ritz, R. Soiffer, Heidi Chen, 2012, Blood.

A multicenter, phase I study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.

Catherine J. Wu, J. Ritz, S. Nikiforow, 2020, Blood.

Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

R. Soiffer, A. Fathi, Yi-Bin Chen, 2021, Transplantation and cellular therapy.

Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3‐ITD acute myeloid leukaemia in first complete remission

S. Nikiforow, K. Ballen, D. DeAngelo, 2016, British journal of haematology.

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

J. Ritz, D. Zahrieh, D. Fisher, 2004, Blood.

stem cell transplantation veno-occlusive disease in patients who undergo myeloablative allogeneic Prior gemtuzumab ozogamicin exposure significantly increases the risk of

P. Richardson, D. Zahrieh, D. DeAngelo, 2013 .

Severe acute gastrointestinal graft-vs-host disease: an emerging surgical dilemma in contemporary cancer care.

S. Ashley, M. Zinner, C. Raut, 2008, Archives of surgery.

How I treat How we treat oral chronic graft-versus-host disease

N. Treister, C. Cutler, L. Lehmann, 2012 .

Reprint of: B cells in chronic graft-versus-host disease.

J. Ritz, B. Blazar, C. Cutler, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

B cells in chronic graft-versus-host disease.

J. Ritz, B. Blazar, C. Cutler, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.

J. Ritz, J. Serody, A. Deal, 2012, Blood.

Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.

J. Qi, J. Bradner, A. Melnick, 2019, Blood.

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.

B. Storer, T. Panzarella, M. Aljurf, 2016, Blood.

Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors.

A. Nademanee, H. Lazarus, R. Gingrich, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?

R. Storb, C. Cutler, J. Antin, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Emily M. Thrash, Emma S. Hathaway, Shuqiang Li, 2021, Blood.

Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD AML

A. Lane, S. Verselis, K. Ballen, 2014 .

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.

A. Lane, S. Verselis, K. Ballen, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies.

Stephanie J. Lee, B. Blazar, S. Pavletic, 2022, Transplantation and cellular therapy.

Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease.

P. Armand, R. Soiffer, C. Cutler, 2021, Transplantation and cellular therapy.

Ibrutinib in Steroid-Refractory Chronic Graft-Versus-Host Disease, a Single-Center Experience.

R. Soiffer, J. Pidala, S. Jaglowski, 2021, Transplantation and cellular therapy.

The Chronic Graft-vs.-Host Disease Failure-Free Survival (cGVHD-FFS) index.

B. Storer, J. Pidala, Stephanie J. Lee, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.

A. Logan, D. Miklos, M. Flowers, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study.

J. Pidala, Stephanie J. Lee, M. Flowers, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.

B. Storer, J. Pidala, Stephanie J. Lee, 2017, Blood.

Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.

P. Westervelt, M. Horowitz, Stephanie J. Lee, 2016, JAMA oncology.

Pulmonary symptoms measured by the NIH Lung score predict overall survival, non-relapse mortality and patient-reported outcomes in chronic GVHD

W. Wood, B. Kurland, J. Pidala, 2014 .

Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.

W. Wood, B. Kurland, J. Pidala, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.

D. Paniagua, C. Cutler, A. Viswanathan, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of HLA‐Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Meta‐Analysis

C. Cutler, K. Stopsack, K. Mak, 2016, American journal of hematology.

It takes a village ( of therapies ) to achieve optimal long-term outcomes for multiple myeloma

B. Sandmaier, J. Dipersio, C. Bollard, 2022 .

Short Telomere Length Predicts Non-Relapse Mortality after Stem Cell Transplantation for Myelodysplastic Syndrome.

D. Neuberg, Suneet Agarwal, D. Steensma, 2020, Blood.

Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.

J. Ritz, K. Stevenson, R. Soiffer, 2011, Blood.

BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation.

J. Ritz, S. Nikiforow, P. Armand, 2020, Blood advances.

BK polyomavirus reactivation after reduced-intensity double umbilical cord blood cell transplantation.

K. Ballen, V. Boussiotis, F. Marty, 2015, Transplant immunology.

KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation

J. Ritz, P. Armand, R. Soiffer, 2013, Bone Marrow Transplantation.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report.

G. Cuvelier, J. Pidala, H. Greinix, 2021, Transplantation and cellular therapy.

Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.

J. Ritz, J. Serody, D. Miklos, 2017, Blood.

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.

J. Byrd, G. Freeman, J. Ritz, 2014, Blood.

Manifestations and Treatment of Acute Graft‐versus‐Host Disease

C. Cutler, J. Antin, 2009 .

Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner.

J. Ritz, D. Munn, J. Serody, 2016, Blood.

α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.

T. Braun, R. Soiffer, C. Dinarello, 2018, Blood.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report.

J. Pidala, H. Greinix, V. Bhatt, 2021, Transplantation and cellular therapy.

The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis

R. Vij, Lixin Yang, M. Aljurf, 2022, Haematologica.

Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients.

P. Armand, R. Soiffer, S. Koo, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Invasive Yeast Infection After Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome.

S. Nikiforow, R. Soiffer, C. Cutler, 2022, Transplantation and cellular therapy.

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.

J. Ritz, K. Stevenson, R. Soiffer, 2009, Blood.

graft-versus-host disease Altered B-cell homeostasis and excess BAFF in human chronic

J. Ritz, K. Stevenson, R. Soiffer, 2009 .

ncillary Therapy and Supportive Care of Chronic raft-versus-Host Disease : National Institutes of ealth Consensus Development Project on Criteria or Clinical Trials in Chronic Graft-versus-Host isease : V . Ancillary Therapy and Supportive Care orking Group Report

L. Gerber, J. Bolaños-Meade, Stephanie J. Lee, 2006 .

A novel TERC CR4/CR5 domain mutation causes telomere disease via decreased TERT binding.

M. Fleming, Suneet Agarwal, C. Cutler, 2016, Blood.

GVHD prevention: an ounce is better than a pound.

D. Weisdorf, G. Socié, C. Cutler, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation.

B. Djulbegovic, J. Pidala, C. Anasetti, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era

C. Cutler, J. Antin, 2006, Current hematologic malignancy reports.

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.

P. Armand, R. Soiffer, C. Cutler, 2007, Blood.

Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis.

P. Armand, R. Soiffer, S. Koo, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis

J. Ritz, J. Brown, K. Stevenson, 2011, Bone Marrow Transplantation.

Generic immunosuppressants in hematopoietic cell transplantation.

Ya-Chen Tina Shih, A. Kesselheim, F. Appelbaum, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A multicenter, retrospective, case‐cohort study of the epidemiology and risk factors for Clostridium difficile infection among cord blood transplant recipients

K. Ballen, D. Braun, D. Leffler, 2017, Transplant infectious disease : an official journal of the Transplantation Society.

B. Yeap, K. Ballen, R. Soiffer, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

syndrome and acute myeloid leukemia Allogeneic transplantation for therapy-related myelodysplastic

J. Sierra, J. Dipersio, S. Tarima, 2011 .

Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.

J. Sierra, J. Dipersio, S. Tarima, 2010, Blood.

Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?

G. Abel, R. Soiffer, D. Steensma, 2016, Bone Marrow Transplantation.

Case records of the Massachusetts General Hospital. Case 38-2007. A 44-year-old woman with generalized, painful, ulcerated skin lesions.

C. Cutler, V. Liu, Alison Z. Young, 2007, The New England journal of medicine.

Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease.

Maria E. Kempner, J. Ritz, M. Perales, 2015, Blood.

TRANSPLANTATION Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease

Maria E. Kempner, J. Ritz, M. Perales, 2017 .

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis

B. Sandmaier, M. Aljurf, R. Gale, 2016, Cancer.

A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS

M. Cazzola, H. Deeg, P. Greenberg, 2011 .

Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.

J. Ritz, P. Armand, D. DeAngelo, 2006 .

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

Annette S. Kim, A. Letai, S. Nikiforow, 2021, Blood advances.

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.

C. Bloomfield, R. Larson, K. Mrózek, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

J. Wingard, K. Ballen, Y. Nieto, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.

P. Armand, D. Fisher, R. Soiffer, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation

C. Cutler, J. Antin, 2004, Bone Marrow Transplantation.

Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

M. Horowitz, R. Gale, Stephanie J. Lee, 2012, Blood.

Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation

E. Estey, B. Sandmaier, M. Krem, 2021, Bone Marrow Transplantation.

Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.

J. Gribben, J. Ritz, D. Fisher, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.

E. Shpall, J. Wingard, K. Ballen, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II Trial of Parathyroid Hormone following Double Umbilical Cord Blood Transplantation

E. Shpall, J. Wingard, K. Ballen, 2012 .

Current and novel therapies in acute GVHD.

C. Cutler, V. Ho, 2008, Best practice & research. Clinical haematology.

Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation

J. Ritz, S. Nikiforow, C. Ng, 2022, Haematologica.

NCCN Guidelines: Pretransplant Recipient Evaluation and Management of Graft-Versus-Host Disease.

S. Pavletic, C. Cutler, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.

M. A. Abu Zaid, Juan Wu, S. Choi, 2017, Blood.

Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, P. Armand, 2017, Blood.

A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, P. Armand, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

W. Wood, B. Storer, J. Pidala, 2016, Blood.

Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host-disease.

M. Mihm, G. Pinkus, J. Ritz, 2020, The Journal of clinical investigation.

Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults.

J. Ritz, K. Ballen, T. Karantanos, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Targeting PI3Kδ function for amelioration of murine chronic graft‐versus‐host disease

J. Byrd, K. Okkenhaug, J. Ritz, 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

J. Byrd, J. Ritz, D. Munn, 2014, The Journal of clinical investigation.

Chronic graft-versus-host disease (cGVHD) is a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and current therapies do not completely prevent and/or treat cGVHD. CD4

J. Byrd, J. Ritz, D. Munn, 2014 .

Mammalian target of rapamycin inhibitor-associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease.

A. Villa, S. Sonis, D. Peterson, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Acute Graft Versus Host Disease: Prophylaxis

C. Cutler, J. Antin, V. Ho, 2010 .

Comparison of Tacrolimus and Sirolimus ( Tac / Sir ) versus Tacrolimus , Sirolimus , and mini-methotrexate ( Tac / Sir / Mtx ) as Acute GVHD Prophylaxis after Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

R. Soiffer, C. Cutler, Haesook T. Kim, 2009 .

Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.

R. Soiffer, Shuli Li, C. Cutler, 2007, Blood.

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.

J. Ritz, K. Stevenson, P. Armand, 2009, Blood.

Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease

S. Nikiforow, P. Armand, R. Soiffer, 2020, Bone Marrow Transplantation.

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.

L. Zon, W. Goessling, C. Desponts, 2013, Blood.

Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.

J. Ritz, P. Armand, K. Ballen, 2011, Blood.

Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease

J. Ritz, S. Nikiforow, J. Whangbo, 2022, Blood advances.

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

A. Logan, D. Howard, J. Liesveld, 2021, Blood.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report Transplantation and Cellular Therapy

J. Pidala, H. Greinix, V. Bhatt, 2021 .

Effect of sirolimus on immune reconstitution following myeloablative allogeneic stem-cell transplantation: An ancillary analysis of a randomized controlled trial comparing Tacrolimus/Sirolimus with Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).

J. Ritz, R. Soiffer, S. Choi, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.

J. Ritz, S. Nikiforow, J. Whangbo, 2016, Blood.

Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.

J. Ritz, J. Serody, R. Soiffer, 2015, Blood.

High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease

J. Ritz, K. Stevenson, R. Soiffer, 2007, Clinical Cancer Research.

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions.

P. Richardson, R. Soiffer, C. Cutler, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease

P. Richardson, S. Mineishi, D. Niederwieser, 2012, Therapeutic advances in hematology.

Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network

M. Horowitz, J. Bolaños-Meade, Stephanie J. Lee, 2016 .

Peer support in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT): a qualitative study

L. Traeger, E. Feig, Lauren E. Harnedy, 2022, Bone Marrow Transplantation.

Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant.

Jeffrey S. Miller, M. MacMillan, Juan Wu, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

In response to "American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults".

P. Hari, B. Sandmaier, S. Davies, 2020, Blood advances.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report Transplantation and Cellular Therapy

Shannon R. McCurdy, R. Jenq, R. Lafyatis, 2021 .

TRANSPLANTATION Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease

J. Ritz, J. Serody, R. Soiffer, 2015 .

BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation.

J. Ritz, S. Nikiforow, P. Armand, 2016, Blood advances.

Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse

Michal Sheffer, Catherine J. Wu, J. Ritz, 2022, The Journal of clinical investigation.

Recurrent Acute Pulmonary Toxicity and Respiratory Failure Associated with Fludarabine Monophosphate

P. Corris, C. Cutler, Y. Samman, 1997 .

Circulating T follicular helper cells with increased function during chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, P. Armand, 2016, Blood.

Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease

J. Pidala, Stephanie J. Lee, M. Flowers, 2015, Haematologica.

transplantation Risk factors for acute GVHD and survival after hematopoietic cell

M. Horowitz, R. Gale, Stephanie J. Lee, 2012 .

Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide.

Catherine J. Wu, J. Ritz, S. Nikiforow, 2021, Blood advances.

HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies.

M. Aljurf, B. George, M. Flowers, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transplantation for MDS in the elderly: more evidence, or more bias?

C. Cutler, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Catherine J. Wu, F. Hodi, Michael S. Rooney, 2016, The New England journal of medicine.

Comorbidity Burden in Patients with Chronic Graft Versus Host Disease

W. Wood, B. Storer, J. Pidala, 2014 .

Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis.

I. Bassett, R. Soiffer, S. Browne, 2007, Blood.

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines.

M. Robin, G. Garcia-Manero, Z. DeFilipp, 2022, Transplantation and cellular therapy.

Sequential infusion of donor‐derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation

J. Ritz, R. Soiffer, R. Joyce, 2014, American journal of hematology.

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant

P. Richardson, S. Nikiforow, R. Soiffer, 2021, Blood advances.

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

J. Wingard, K. Ballen, Juan Wu, 2011, Blood.

Oral health in allogeneic hematopoietic stem cells transplantation survivors

A. Villa, P. Fantozzi, N. Treister, 2020, Bone Marrow Transplantation.

Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.

M. Perales, M. Mohty, J. Wingard, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.

R. Soiffer, Paul J. Martin, J. Ferrara, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.

S. Grupp, D. Porter, M. Pasquini, 2014, Blood.

Analysis of gastrointestinal and hepatic chronic grant-versus-host disease manifestations on major outcomes

B. Kurland, J. Pidala, Stephanie J. Lee, 2013 .

Prognostic Impact of Elevated Serum Ferritin in Patients Undergoing Myeloablative Stem Cell Transplantation.

P. Armand, R. Soiffer, C. Cutler, 2006 .

Management of important adverse events associated with inotuzumab ozogamicin: expert panel review

W. Stock, A. Merchant, Stephanie J. Lee, 2018, Bone Marrow Transplantation.

Use of Prescription Sialagogues for Management of Xerostomia in Chronic Graft-versus-Host-Disease.

A. Villa, H. Sroussi, N. Treister, 2021, Transplantation and cellular therapy.

Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, P. Armand, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)

Stephanie J. Lee, O. Schueller, B. Blazar, 2020, Transplantation and Cellular Therapy.

Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation.

M. Horowitz, J. Pidala, Stephanie J. Lee, 2019, JAMA oncology.

A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801

M. Horowitz, J. Bolaños-Meade, Stephanie J. Lee, 2018, Haematologica.

Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized Study.

O. Frankfurt, G. Schiller, P. Stiff, 2021, Blood.

Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis.

B. Storer, A. Kariminia, Stephanie J. Lee, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update

C. Cutler, J. Antin, 2010, Current opinion in hematology.

Prediction of veno-occlusive disease using biomarkers of endothelial injury.

P. Richardson, J. Ritz, P. Armand, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The Addition Of Sirolimus To The Gvhd Prophylaxis Regimen In Reduced Intensity Allogeneic Stem Cell Transplantation For Lymphoma: A Multicenter Randomized Trial

R. Soiffer, Yi-Bin Chen, S. McAfee, 2013 .

Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402

S. Grupp, D. Porter, M. Pasquini, 2012 .

Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.

R. Soiffer, Stephanie J. Lee, C. Magee, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.

S. Nikiforow, P. Armand, K. Ballen, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

transplantation: a cohort analysis cytomegalovirus reactivation after allogeneic hematopoietic stem cell Sirolimus-based graft-versus-host disease prophylaxis protects against

R. Soiffer, S. Browne, F. Marty, 2011 .

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution

Catherine J. Wu, J. Ritz, S. Nikiforow, 2021, Blood advances.

Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with FLT3-ITD AML

S. Verselis, K. Ballen, R. Soiffer, 2014 .

Stem Cell Sources for Allogeneic Transplantation

C. Cutler, 2008 .

An overview of hematopoietic stem cell transplantation.

C. Cutler, J. Antin, 2005, Clinics in chest medicine.

Stem Cell Sources

C. Cutler, J. Antin, 2004 .

Acute a nd C hronic G raft-Versus-Hos t D isease A fter Allogeneic P eripheral-Blood S tem-Cell a nd B one M arrow Transplantation: A M eta-Analysis

D. Paniagua, C. Cutler, A. Viswanathan, 2001 .

An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease.

A. Sultan, P. Armand, R. Soiffer, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comorbidity burden in patients with chronic GVHD

W. Wood, B. Storer, J. Pidala, 2013, Bone Marrow Transplantation.

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.

B. Kurland, J. Pidala, Stephanie J. Lee, 2011, Blood.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Daniel Wolff, Yoshihiro Inamoto, Sandra A Mitchell, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

Hisashi Sakamaki, Hartmut Döhner, Richard Schlenk, 2009, JAMA.

Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.

F. Marty, C. Cutler, K. Fiumara, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience

Catherine J. Wu, S. Nikiforow, C. Jacobson, 2021, Blood Advances.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.

Shannon R. McCurdy, R. Jenq, G. Cuvelier, 2021, Transplantation and cellular therapy.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report

G. Cuvelier, J. Pidala, H. Greinix, 2021, Transplantation and cellular therapy.

How we treat oral chronic graft-versus-host disease.

N. Treister, C. Cutler, L. Lehmann, 2012, Blood.

Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.

J. Ritz, K. Stevenson, P. Armand, 2010, Blood.

Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes.

J. Wagner, F. Appelbaum, K. Ballen, 2010, Blood.

Reduced-intensity conditioning and umbilical cord blood transplantation in adults

K. Ballen, C. Cutler, 2009, Bone Marrow Transplantation.

Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.

M. Tallman, R. Gale, M. Flowers, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.

D. Zahrieh, R. Soiffer, Stephanie J. Lee, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice.

C. Cutler, B. Hamilton, N. Khera, 2022, Transplantation and cellular therapy.

Routine screening for psychosocial distress following hematopoietic stem cell transplantation

P. Richardson, D. Fisher, R. Soiffer, 2005, Bone Marrow Transplantation.

A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome.

E. D. Jacobsen, P. Armand, D. Fisher, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Oral Complications in Hematopoietic Stem Cell Transplantation Survivorship

S. Elad, N. Treister, C. Cutler, 2013 .

Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia

J. Klein, M. Horowitz, J. Wingard, 2014, Clinical Cancer Research.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

A. Ganser, G. Mufti, N. Kröger, 2017, Blood.

Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.

K. Ballen, R. Soiffer, Yi-Bin Chen, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.

Alan M. Miller, R. Vij, F. Baron, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.

P. Armand, K. Ballen, R. Soiffer, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Patient selection for transplantation in the myelodysplastic syndromes.

C. Cutler, 2010, Hematology/oncology clinics of North America.

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

John P Klein, Daniel J Weisdorf, Peter Greenberg, 2004, Blood.

Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors.

E. V. Van Allen, R. Soiffer, B. Reardon, 2018, Oral oncology.

Assessing the relationship between oral chronic graft-versus-host disease and global measures of quality of life.

Stephanie J. Lee, N. Treister, C. Cutler, 2015, Oral oncology.

Interleukin-2 and regulatory T cells in graft-versus-host disease.

J. Ritz, Sashank Prasad, D. Bienfang, 2011, The New England journal of medicine.

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.

D. Zahrieh, R. Soiffer, Stephanie J. Lee, 2004, Blood.

Medical management update: Non-Hodgkin lymphoma.

N. Treister, C. Cutler, H. Mawardi, 2009, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.

J. Ritz, K. Stevenson, P. Armand, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The clinical and functional effects of TERT variants in myelodysplastic syndrome.

D. Neuberg, J. Garber, Suneet Agarwal, 2021, Blood.

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.

Catherine J. Wu, J. Ritz, D. Miklos, 2004, Blood.

Expansion, persistence and efficacy of donor memory-like NK cells for the treatment of post-transplant relapse

J. Ritz, Jianzhu Chen, A. Lane, 2021, medRxiv.

The clinical and functional effects of TERT variants in myelodysplastic syndrome

D. Neuberg, J. Garber, Suneet Agarwal, 2021, bioRxiv.

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.

J. Ritz, D. DeAngelo, R. Soiffer, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Delirium and Healthcare Utilization in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Yi-Bin Chen, C. Lindvall, A. El-Jawahri, 2023, Transplantation and cellular therapy.

Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation.

B. Ebert, M. Ducar, A. Thorner, 2019, Blood advances.

Mechanistic approaches for the prevention and treatment of chronic GVHD.

J. Ritz, C. Cutler, J. Koreth, 2017, Blood.

A disease risk index for patients undergoing allogeneic stem cell transplantation.

H. Deeg, J. Ritz, M. Sorror, 2012, Blood.

High‐resolution HLA matching in double‐umbilical‐cord‐blood reduced‐intensity transplantation in adults

B. Yeap, S. Saidman, K. Ballen, 2009, Transfusion.

Improving outcomes in umbilical cord blood transplantation: state of the art.

K. Ballen, C. Cutler, 2012, Blood reviews.

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, J. Whangbo, 2019, Blood advances.

PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.

J. Ritz, M. Tanimoto, P. Armand, 2017, Blood.

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation

J. Ritz, S. Nikiforow, P. Armand, 2016, Haematologica.

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.

J. Ritz, P. Armand, R. Soiffer, 2013, Blood.

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial

Catherine J. Wu, F. Hodi, G. Dranoff, 2021, Blood advances.

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, J. Whangbo, 2016, Blood.

Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.

Tao Wang, Thomas Spitzer, Daniel J Weisdorf, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Assessment of Joint and Fascia Manifestations in Chronic Graft‐Versus‐Host Disease

J. Goldberg, B. Kurland, J. Pidala, 2014, Arthritis & rheumatology.

Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease

J. Ritz, P. Armand, R. Soiffer, 2013, Science Translational Medicine.

Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation

J. Ritz, S. Nikiforow, C. J. Luckey, 2016, Haematologica.

HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.

R. Schlenk, H. Döhner, A. Ganser, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

D. Neuberg, B. Ebert, P. Stojanov, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.

Alan M. Miller, P. D. Dal Cin, J. Sierra, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy

D. Zahrieh, R. Soiffer, A. Saito, 2007, Bone Marrow Transplantation.

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

J. Gribben, J. Ritz, D. DeAngelo, 2004, Blood.

Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease

D. Fisher, R. Soiffer, E. Milford, 2004, Bone Marrow Transplantation.

Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.

D. Miklos, D. Fisher, R. Soiffer, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.

Catherine J. Wu, D. Miklos, R. Soiffer, 2003, Blood.

Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

P. Armand, K. Ballen, R. Soiffer, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.

W. Wood, J. Pidala, Stephanie J. Lee, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes and management strategies for graft failure after umbilical cord blood transplantation

S. Nikiforow, K. Ballen, R. Soiffer, 2014, American journal of hematology.

Biomarkers for acute GVHD: can we predict the unpredictable?

Yi-Bin Chen, C. Cutler, Y-B Chen, 2013, Bone Marrow Transplantation.

Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.

J. Wagner, J. Kurtzberg, E. Shpall, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients.

J. Ritz, S. Nikiforow, E. Shpall, 2017, Cytotherapy.

Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.

J. Ritz, K. Stevenson, P. Armand, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor-derived second hematologic malignancies after cord blood transplantation.

B. Yeap, K. Ballen, R. Soiffer, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis BMT CTN 1101Open for Accrual June 2012Open for Accrual June 2012.

B. Logan, J. Magenau, C. Cutler, 2022, Transplantation and cellular therapy.

Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells.

Hongye Liu, Masahiro Hirakawa, Kazuyuki Murase, 2016, JCI insight.

Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS).

J. Cortes, M. Horowitz, M. Kalaycio, 2013, Blood.

Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia.

J. Wagner, E. Shpall, L. Isola, 2013, Blood.

transplantation disease prophylaxis in mismatched related donor or unrelated donor Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host

Catherine J. Wu, D. Miklos, R. Soiffer, 2013 .

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report.

M. Mohty, Stephanie J. Lee, S. Pavletic, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.

J. Ritz, P. Armand, K. Ballen, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation

J. Ritz, S. Nikiforow, P. Armand, 2019, Bone Marrow Transplantation.

GVHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes

M. Aljurf, I. Lewis, R. Gale, 2016, Bone Marrow Transplantation.

IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults

J. Ritz, S. Nikiforow, K. Ballen, 2015, PloS one.

Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes.

J. Pidala, L. Rybicki, Stephanie J. Lee, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome.

Catherine J. Wu, P. Armand, R. Soiffer, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

B. Sandmaier, M. Aljurf, R. Gale, 2019, Blood advances.

Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation.

D. Leaf, J. Ritz, P. Armand, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium

B. Kurland, J. Pidala, M. Flowers, 2013, Bone Marrow Transplantation.

Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis.

B. Djulbegovic, M. Mohty, C. Cutler, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation

R. Soiffer, E. Milford, C. Cutler, 2006, Bone Marrow Transplantation.

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts.

J. Wagner, K. Ballen, R. Soiffer, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor-speciﬁc anti-HLA antibodies predict outcome in double umbilical cord blood transplantation

J. Ritz, P. Armand, K. Ballen, 2011 .

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease

J. Ritz, S. Nikiforow, J. Whangbo, 2022, Blood advances.

Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation

S. Nikiforow, P. Armand, R. Soiffer, 2017, Haematologica.

Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.

J. Weiss, J. Ritz, D. Munn, 2016, Blood.

Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.

J. Ritz, P. Armand, C. Jacobson, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

How we treat higher-risk myelodysplastic syndromes.

M. Sekeres, C. Cutler, 2014, Blood.

Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium

B. Kurland, J. Pidala, Stephanie J. Lee, 2011, Haematologica.

Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.

J. Ritz, R. Soiffer, Gregory Bascug, 2011, Blood.

Excellent Disease-Free Survival after Double Cord Blood Transplantation Using a Reduced Intensity Chemotherapy Only Conditioning Regimen in a Diverse Adult Population.

B. Yeap, K. Ballen, R. Soiffer, 2005 .

White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome

J. Ritz, P. Armand, R. Soiffer, 2014, American journal of hematology.

Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.

J. Ritz, P. Armand, R. Soiffer, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.

P. Armand, R. Soiffer, C. Cutler, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.

J. Ritz, P. Armand, R. Soiffer, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

C. Cutler, J. Antin, 2004, Cancer.

High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.

J. Gribben, J. Ritz, D. DeAngelo, 2004 .

Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival.

J. Ritz, S. Nikiforow, P. Armand, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome

J. Ritz, P. Armand, R. Soiffer, 2014 .

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.

J. Ritz, S. Nikiforow, P. Armand, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated

S. Nikiforow, H. Nakasone, J. Pidala, 2018, Haematologica.

Novel drugs for the prevention and treatment of acute GVHD.

C. Cutler, J. Antin, 2008, Current pharmaceutical design.

Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome

J. Gribben, Catherine J. Wu, J. Ritz, 2012, Leukemia.

An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.

J. Ritz, J. Serody, Jianfei Yang, 2017, JCI insight.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

W. Wood, J. Pidala, E. Holler, 2018, Blood advances.

A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.

J. Ritz, S. Nikiforow, P. Armand, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.

M. Cazzola, H. Deeg, P. Greenberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

E. Leifer, P. Westervelt, F. Appelbaum, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

E. Leifer, P. Westervelt, F. Appelbaum, 2020, Transplantation and Cellular Therapy.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME

Alan M. Miller, J. Vose, S. Montoto, 2014, Bone Marrow Transplantation.

Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease.

K. Ballen, Yi-Bin Chen, A. El-Jawahri, 2017, Blood advances.

TRANSPLANTATION Ef ﬁ cacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease

J. Ritz, S. Nikiforow, J. Whangbo, 2016 .

Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study

B. Kurland, J. Pidala, M. Arora, 2013, Leukemia.

Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study.

B. Kurland, J. Pidala, Stephanie J. Lee, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease.

B. Storer, J. Pidala, Stephanie J. Lee, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study

B. Storer, J. Pidala, Stephanie J. Lee, 2012, Haematologica.

Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis.

R. Soiffer, S. Koo, F. Marty, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation

B. Yeap, K. Ballen, R. Soiffer, 2008, Bone Marrow Transplantation.

Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.

J. Klein, M. Horowitz, J. Wingard, 2011, Blood.

Biomarker Panel for Chronic Graft-Versus-Host Disease.

Philip R. Gafken, Y. Ogata, B. Storer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.

Catherine J. Wu, J. Ritz, S. Nikiforow, 2020, Blood advances.

Incidence, predictors, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome after reduced intensity allogeneic hematopoietic cell transplantation.

P. Richardson, S. Nikiforow, P. Armand, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

34: Characterization of B Cell Target Antigens in Patients with Chronic Graft Versus Host Disease

Catherine J. Wu, V. Brusic, J. Ritz, 2008 .

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.

P. Armand, R. Soiffer, C. Cutler, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prior rituximab correlates with less acute graft‐versus‐host disease and better survival in B‐cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation

R. Gale, H. Khoury, O. Ringdén, 2009, British journal of haematology.

Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.

A. LaCasce, A. Freedman, P. Armand, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.

R. Soiffer, Shuli Li, C. Cutler, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.

A. LaCasce, A. Freedman, P. Armand, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Topical sirolimus for management of refractory oral chronic graft-versus-host disease.

R. Soiffer, N. Treister, Shuli Li, 2020, Oral diseases.

Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT.

M. Mihm, G. Dranoff, J. Ritz, 2017, Blood advances.

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.

P. Richardson, K. Stevenson, P. Armand, 2008, Blood.

Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial

Catherine J. Wu, J. Ritz, S. Nikiforow, 2020 .

Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.

J. Gribben, J. Ritz, K. Stevenson, 2008 .

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results

J. Ritz, S. Nikiforow, P. Armand, 2018, Haematologica.

HLA mismatch and clinical outcome after unrelated donor (URD) non-myeloablative hematopoietic stem cell transplantation (NST)

R. Soiffer, E. Milford, C. Cutler, 2005 .

Next‐generation sequencing‐based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma

V. Carlton, J. Ritz, M. Faham, 2016, British journal of haematology.

Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells.

J. Ritz, K. Ballen, T. Karantanos, 2019, Clinical immunology.

Cord colitis syndrome in cord-blood stem-cell transplantation.

A. Bellizzi, K. Ballen, R. Soiffer, 2011, New England Journal of Medicine.

Sirolimus and thrombotic microangiopathy after allogeneic stem cell transplantation

Sigui Li, R. Soiffer, C. Magee, 2005 .

The addition of sirolimus to the graft‐versus‐host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial

P. Armand, R. Soiffer, Yi-Bin Chen, 2016, British journal of haematology.

Clinical benefit of response in chronic graft-versus-host disease.

B. Storer, J. Pidala, Stephanie J. Lee, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium.

J. Pidala, Stephanie J. Lee, D. Weisdorf, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.

J. Ritz, P. Armand, R. Soiffer, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research

J. Szer, M. Tallman, K. Ballen, 2013, Haematologica.

Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation

S. Nikiforow, P. Armand, R. Soiffer, 2015, Haematologica.

Rituxan for steroid-refractory chronic GVHD

J. Ritz, D. Miklos, D. Bienfang, 2005 .

Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.

J. Ritz, D. Miklos, D. Bienfang, 2004 .

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.

J. Ritz, P. Armand, D. DeAngelo, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.

J. Ritz, S. Nikiforow, J. Whangbo, 2019, Blood advances.

A multicenter open-label phase 1b/2 study of ibrutinib in steroid dependent or refractory chronic graft versus host disease (cGVHD).

D. Miklos, M. Arora, S. Jaglowski, 2015 .

Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies

J. Qi, J. Bradner, A. Melnick, 2014 .

Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation

A. Letai, J. Ritz, P. Armand, 2014, Haematologica.

Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.

J. Ritz, P. Armand, R. Soiffer, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation

Catherine J. Wu, J. Ritz, S. Nikiforow, 2021, Haematologica.

Denileukin diftitox (ONTAK) as targeted therapy against steroid refractory graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)

J. Ritz, D. Zahrieh, R. Soiffer, 2004 .

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium

J. Pidala, Z. DeFilipp, Stephanie J. Lee, 2021, Blood advances.

Machine learning reveals chronic graft-versus-host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies

J. Irish, Heidi Chen, J. Pidala, 2018, Haematologica.

Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation.

P. Armand, R. Soiffer, C. Cutler, 2012 .

Economic and Practical Considerations in the Treatment of Oral Mucosal Chronic Graft-Versus-Host Disease.

J. Liesveld, S. Elad, N. Treister, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans In a Preclinical Model

J. Byrd, G. Freeman, J. Ritz, 2013 .

Validation of measurement scales in ocular graft-versus-host disease.

B. Kurland, J. Pidala, Stephanie J. Lee, 2012, Ophthalmology.

Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids

A. Logan, D. Miklos, M. Flowers, 2016 .

Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD)

J. Ritz, M. Perales, R. Soiffer, 2016 .

Feasibility, Safety, Efficacy And Immunologic Impact Of Daily Ultra-Low-Dose Interleukin-2 For Steroid-Refractory Chronic Graft-Versus-Host Disease: A Phase I Study

J. Ritz, K. Stevenson, P. Armand, 2010 .

High Rate of Second Malignancies after Reduced Intensity Double Cord Blood Transplants in Adults.

B. Yeap, K. Ballen, R. Soiffer, 2008 .

Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials

Z. DeFilipp, Stephanie J. Lee, B. Blazar, 2022, Blood advances.

Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival

J. Pidala, Stephanie J. Lee, M. Arora, 2021, Blood advances.

transplantation in adults depends on reconstitution of thymopoiesis Clearance of CMV viremia and survival after double umbilical cord blood

J. Ritz, K. Stevenson, P. Armand, 2013 .

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.

P. Richardson, S. Nikiforow, P. Armand, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transplant survivorship: a call to arms.

C. Cutler, 2010, Blood.

age hematopoietic cell transplantation for patients older than 50 years of Comparative outcome of nonmyeloablative and myeloablative allogeneic

J. Gribben, J. Ritz, D. DeAngelo, 2013 .

Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease

J. Pidala, Stephanie J. Lee, M. Arora, 2022, Haematologica.

Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort.

J. Klein, M. Horowitz, J. Wingard, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Improved survival after acute graft-versus-host disease diagnosis in the modern era

Alan M. Miller, R. Vij, W. Wood, 2017, Haematologica.

Does iron overload really matter in stem cell transplantation?

R. Kwong, E. Neufeld, P. Armand, 2011, American journal of hematology.

Yin and Yang of Psychological Health in the Cancer Experience: Does Positive Psychology Have a Role?

L. Traeger, J. Huffman, A. El-Jawahri, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A positive psychology intervention to promote health outcomes in hematopoietic stem cell transplantation: The PATH proof-of-concept trial

B. Healy, Lauren E. Harnedy, C. Celano, 2021, Bone Marrow Transplantation.

Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research

S. Spellman, Tao Wang, M. Arora, 2013 .

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Yi-Bin Chen, S. Devine, C. Cutler, 2019, Blood advances.

High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.

N. Munshi, P. Richardson, B. Djulbegovic, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors.

B. George, M. Grunwald, D. Weisdorf, 2021, Blood advances.

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.

B. Sandmaier, M. Perales, A. Nagler, 2020, Blood advances.

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

W. Wood, J. Pidala, E. Holler, 2017 .

The development of graft-versus-host disease prophylaxis

C. Cutler, 2023, Haematologica.

igh-dose Therapy with Single Autologous ransplantation versus Chemotherapy for Newly iagnosed Multiple Myeloma : A Systematic Review nd Meta-analysis of Randomized Controlled Trials

N. Munshi, P. Richardson, B. Djulbegovic, 2007 .

Incidence of acute and chronic GVHD after allogeneic peripheral blood stem cell and bone marrow transplantation: A meta-analysis

D. Paniagua, C. Cutler, A. Viswanathan, 2000 .

Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.

W. Wood, J. Pidala, Yi-Bin Chen, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.

P. Armand, R. Soiffer, J. Plutzky, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sirolimus, Tacrolimus and Reduced-Dose Methotrexate as Graft Versus Host Disease (GVHD)Prophylaxis after Non-Myeloablative Stem Cell Transplantation: Low Incidence of Acute GVHD Compared with Tacrolimus/Methotrexate or Cyclosporine/Prednisone.

J. Gribben, J. Ritz, D. Fisher, 2004 .

Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.

P. Greenberg, M. Horowitz, B. Logan, 2019, JAMA oncology.

Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome – not because we can, but because we should

C. Cutler, 2017, Haematologica.

Impact of conditioning regimen intensity on the outcomes of peripheral T‐cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T‐cell lymphoma patients undergoing allogeneic transplant

K. Ahn, M. Shadman, C. Cutler, 2022, British journal of haematology.

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

W. Chan, D. Weisenburger, A. Nademanee, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical Features of AKI in the Early Post-Transplant Period Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation.

D. Leaf, S. Nikiforow, R. Soiffer, 2023, Transplantation and cellular therapy.

mpact of Conditioning Regimen Intensity n Outcome of Allogeneic Hematopoietic Cell ransplantation for Advanced Acute Myelogenous eukemia and Myelodysplastic Syndrome

J. Ritz, D. DeAngelo, R. Soiffer, 2006 .

337: Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis

K. Ballen, R. Soiffer, T. Spitzer, 2007 .

Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America.

G. Abel, W. Wood, J. Pidala, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Measurement of Oral Chronic Graft-Versus-Host Disease

B. Kurland, J. Pidala, M. Flowers, 2012 .

B. Kurland, M. Flowers, M. Arora, 2012 .

Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome.

D. Neuberg, Suneet Agarwal, D. Steensma, 2020, Blood.

Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402

D. Weisdorf, B. Blazar, M. Verneris, 2017, Bone Marrow Transplantation.

The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease.

Heidi Chen, J. Pidala, Stephanie J. Lee, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT

J. Ritz, S. Nikiforow, K. Ballen, 2014, Blood Cancer Journal.

The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation.

P. Armand, R. Soiffer, J. Blossom, 2012, Biology of Blood and Marrow Transplantation.

Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy

P. Armand, R. Soiffer, C. Cutler, 2010, Bone Marrow Transplantation.

undergoing myeloablative stem cell transplantation Prognostic impact of elevated pre-transplant serum ferritin in patients

P. Armand, C. Cutler, Haesook T. Kim, 2013 .

Yan Song, A. Sung, W. Hwang, 2022, Transplantation and cellular therapy.

Multimodal AGuIX® Nanoparticles: Size Characterization by HF5 and Optimization of the Radiolabeling with Various SPECT/PET/Theranostic Tracers

O. Tillement, F. Lux, S. Huclier-Markai, 2019 .

Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings.

D. Neuberg, Catherine J. Wu, J. Ritz, 2022, Blood.

Disseminated varicella-zoster virus infections following messenger RNA–based COVID-19 vaccination

C. Lian, N. LeBoeuf, J. Merola, 2021, JAAD Case Reports.

BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.

J. Qi, J. Bradner, J. Ritz, 2022, Blood.

Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation

D. Neuberg, B. Ebert, K. Hsu, 2016 .

Stephanie J. Lee, B. Shaw, K. Flynn, 2022, American journal of hematology.

Feasibility of a positive psychology intervention (PATH) in allogeneic hematopoietic stem cell transplantation survivors: Randomized pilot trial design and methods.

L. Traeger, H. Jim, B. Healy, 2023, Contemporary clinical trials.

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.

J. Kurtzberg, O. Frankfurt, D. Cilloni, 2023, Transplantation and cellular therapy.

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis

A. LaCasce, S. Nikiforow, D. Fisher, 2022, Blood advances.

CD25+ Regulatory T CELL-Depleted Donor Lymphocyte Infusion for Relapse After Allogeneic Transplantation – A PHASE 1 Study

J. Ritz, S. Nikiforow, P. Armand, 2013 .

Medication Adherence in Patients with Hematologic Malignancies who are Hematopoietic Stem Cell Transplantation Survivors: A Qualitative Study.

L. Traeger, A. El-Jawahri, C. Cutler, 2023, Transplantation and cellular therapy.

Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation

K. Cibulskis, D. Neuberg, B. Ebert, 2012 .

FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation

W. Goessling, C. Desponts, J. Ritz, 2011 .

Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study

H. Deeg, S. Spellman, S. Gadalla, 2023, Journal of Hematology & Oncology.

Impaired Immune Reconstitution after Cord Blood Transplantation in Adults Is Associated with Delayed Recovery but Not Functional Impairment of CD8+T Cells.

J. Ritz, K. Stevenson, K. Ballen, 2007 .

Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease.

S. Nikiforow, R. Soiffer, R. Joyce, 2023, Blood.

Reply to J. Mehta

A. LaCasce, A. Freedman, P. Armand, 2009 .

Acute Graft Versus Host Disease: Prophylaxis

C. Cutler, J. Antin, V. Ho, 2010 .

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD

Catherine J. Wu, J. Ritz, S. Nikiforow, 2023, Blood Advances.

Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells

Catherine J. Wu, J. Ritz, S. Nikiforow, 2023, Blood Advances.

54: Inclusion of Sirolimus in the GVHD Prophylaxis Regimen is Associated with Improved Survival in Patients with Lymphoma Undergoing Allogeneic Transplantation

A. LaCasce, A. Freedman, P. Armand, 2008 .

Tacrolimus and Sirolimus without Methotrexate as Acute GVHD Prophylaxis after Matched Related Donor Reduced Intensity Conditioning (RIC) Stem Cell Transplantation (SCT).

P. Armand, R. Soiffer, Shuli Li, 2007 .

PD-1 modulates regulatory T cell homeostasis during low-dose IL-2 therapy

J. Ritz, M. Tanimoto, P. Armand, 2017 .

A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Catherine J. Wu, S. Nikiforow, P. Armand, 2018, Blood.

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.

L. Zon, W. Goessling, C. Desponts, 2013, Blood.

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

I. Yakoub-Agha, M. Aljurf, R. Gale, 2023, Blood advances.

Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.

M. A. Abu Zaid, Juan Wu, S. Choi, 2017, Blood.

First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

J. Wingard, K. Ballen, Y. Nieto, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Circulating T follicular helper cells with increased function during chronic graft-versus-host disease.

J. Ritz, S. Nikiforow, P. Armand, 2016, Blood.

Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.

J. Ritz, J. Serody, D. Miklos, 2017, Blood.

Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.

B. Storer, J. Pidala, Stephanie J. Lee, 2011, Blood.

An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.

B. Storer, J. Pidala, Stephanie J. Lee, 2017, Blood.

Peripheral-blood stem cells versus bone marrow from unrelated donors.

P. Westervelt, S. Mineishi, D. Porter, 2012, The New England journal of medicine.

Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort.

M. Horowitz, J. Wingard, R. Gale, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome.

Catherine J. Wu, P. Armand, R. Soiffer, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Patient-reported treatment response in chronic graft-versus-host disease.

J. Pidala, A. Im, M. Flowers, 2023, Haematologica.

Mechanistic approaches for the prevention and treatment of chronic GVHD.

J. Ritz, C. Cutler, J. Koreth, 2017, Blood.

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

F. Hodi, P. Armand, M. Davids, 2016, The New England journal of medicine.

α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.

T. Braun, R. Soiffer, C. Dinarello, 2018, Blood.

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

A. Logan, D. Miklos, M. Flowers, 2017, Blood.

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

R. Schlenk, H. Döhner, J. Sierra, 2009, JAMA.

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.

D. Neuberg, Catherine J. Wu, G. Dranoff, 2013, The Journal of clinical investigation.

Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intentsity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis

S. Montoto, Sonali M. Smith, D. Maloney, 2013 .

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

B. Sandmaier, M. Aljurf, R. Gale, 2019, Blood advances.

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.

J. Ritz, P. Armand, R. Soiffer, 2013, Blood.

Dental evaluation and clearance prior to allogeneic hematopoietic cell transplantation.

T. Gooley, P. Hujoel, H. Sroussi, 2023, Oral diseases.

Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.

D. Paniagua, C. Cutler, A. Viswanathan, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation

H. Deeg, S. Spellman, S. Gadalla, 2023, Journal of Hematology & Oncology.

Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.

J. Ritz, K. Stevenson, P. Armand, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.

J. Ritz, K. Stevenson, P. Armand, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors – An Analysis of the CIBMTR

M. Horowitz, R. Gale, Stephanie J. Lee, 2010 .

Low-Dose Interleukin-2 Therapy Enhances Cytotoxicity of CD56bright NK Cells in Patients with Chronic Gvhd

J. Ritz, S. Nikiforow, J. Whangbo, 2018, Blood.

Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis.

P. Armand, K. Ballen, R. Soiffer, 2007 .

Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.

J. Ritz, K. Stevenson, P. Armand, 2010, Blood.